Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 7Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Teratoma 1

Interventions

relacorilant 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Peritoneal Neoplasms × Gynecologic × Clear all
NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡